# Avelas Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avelas-biosciences

- Industry: Biotechnology
- Headquarters: US
- Website: www.avelasbio.com
- Total disclosed funding: $35M
- Latest round: Series C (Aug 18, 2016)
- Investors on record: 8

## About

Avelas Biosciences, Inc. develops innovative diagnostic solutions aimed at improving cancer treatment outcomes through advanced technologies, enhancing patient care and precision medicine.Avelas Biosciences specializes in the development of diagnostics for cancer treatment. The company raised USD 20.000 mn in Series C financing in August 2016, led by Pharmstandard International and supported by investors like Ervington Investments Limited and Alexandria Venture Investments. Avelas is headquartered in the US. The founder, whose previous ventures are not documented, has a background in the biotech sector.Avelas Biosciences offers diagnostic solutions designed to enhance cancer treatment decision-making. Their product suite includes advanced imaging technologies and molecular diagnostics aimed at improving the precision of cancer therapies. These solutions target healthcare providers and oncologists, facilitating better patient outcomes through personalized treatment approaches. Avelas serves clients primarily in North America, with a focus on innovative solutions that address the complexities of cancer care.Avelas Biosciences generates revenue through a combination of product sales and partnerships with healthcare institutions. Their financial model is built on transactional sales of diagnostic products, in addition to collaborative agreements with medical facilities that enhance service offerings. This diversified approach aims to strengthen their revenue base while fostering long-term relationships with healthcare providers.Avelas Biosciences is focused on expanding its portfolio with new diagnostic products aimed at enhancing cancer treatment effectiveness. The company plans to introduce additional technologies by 2025, targeting new markets in Europe and Asia to broaden its global reach. The recent funding of USD 20.000 mn will support these initiatives, particularly in product development and market expansion efforts, enhancing their capacity to deliver innovative solutions in oncology.

## Funding rounds

- Series C, Aug 18, 2016, $20M — Avalon Ventures, Alexandria Venture Investments, 6 Dimensions Capital, phs ventures, Ervington Investments, Bregua Corporation
- Series B, Sep 10, 2014, $0.6M — Avalon Ventures, 6 Dimensions Capital, Torrey Pines Investment
- Series B, Jan 9, 2013, $6.8M — Avalon Ventures, Torrey Pines Investment, Wuxi AppTec Group
- Series A, Dec 6, 2012, $7.7M — Avalon Ventures

## Investors

- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series A, Series B, Series C
- Torrey Pines Investment (https://capitalatlas.ai/funds/torrey-pines-investment) — Series B
- Wuxi AppTec Group — Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series C
- phs ventures — Series C
- Ervington Investments (https://capitalatlas.ai/funds/ervington-investments) — Series C
- Bregua Corporation — Series C